Attached files

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (Date of Earliest event Reported): November 19, 2013


                             LIFE STEM GENETICS INC.
             (Exact name of registrant as specified in its charter)

             Nevada                     333-183814                80-0832746
 (State or other jurisdiction of       (Commission              (IRS Employer
of incorporation or organization)      File Number)          Identification No.)

           433 North Camden Drive, Suite 400, Beverly Hills, CA 90210
                    (Address of principal executive offices)

                                 (310) 279-5234
              (Registrant's telephone number, including area code)

          (Former name or former address, if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications  pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule  14a-12  under the  Exchange  Act
    (17CFR240.14a-12)

[ ] Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
    Exchange Act (17CFR240.14d-2(b))

[ ] Pre-commencement  communications  pursuant  to Rule  13e-4(c)  under the
    Exchange Act (17CFR240.13e-4(c))

ITEM 1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT

Effective November 19, 2013, we entered into a private placement  agreement with
one person  (the  "SUBSCRIBER").  Pursuant  to the  agreement,  we agreed to the
issuance of 300,000  units (each,  a "UNIT") at a price of $1.00 per Unit.  Each
Unit  consisted  of one share of our common stock (a "SHARE") and one warrant (a
"WARRANT").  Each Warrant is exercisable by the Subscriber into one common share
of our company stock (a "WARRANT SHARE") at price of $1.00 per Warrant Share for
a period of 12  months.  The total  proceeds  from this  private  placement  was
$300,000.

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

On November  19, 2013,  we issued an  aggregate of 300,000  shares of our common
stock pursuant to the private placement agreement referred to above.

We issued an aggregate  of 300,000  shares of our common stock to one (1) non-US
person (as that term is defined in Regulation S of the  Securities Act of 1933),
in an offshore  transaction  relying on  Regulation S of the  Securities  Act of
1933, as amended.

ITEM 7.01 REGULATION FD DISCLOSURE

In  connection  with the October 21, 2013 private  placement for an aggregate of
$500,000,  we have now closed an aggregate of $800,000 of our planned $1,000,000
private placement of Units. We did not receive funds for the previously  closing
of the remaining $200,000 as announced on November 19, 2013. As a result, we are
continuing to attempt to complete our planned financing of $1 million of Units.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

10.1 Form of Subscription Agreement between our company and the Subscriber.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated: December 10, 2013

LIFE STEM GENETICS INC.


By: /s/ Gloria Simov
   -----------------------------------------------
   Gloria Simov
   President, Chief Executive Officer and Director